U.S. Markets open in 5 hrs 28 mins

Aratana Therapeutics, Inc. (PETX)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
7.24+0.16 (+2.26%)
At close: 4:00PM EDT
People also watch
  • Over a million shares traded on Friday! Given that the Biotechnology indexes had gone up so much last week, PETX should have gone up even more than it did. So, at least we can say that we are losing all of the nonbelievers. Plenty of room for everybody who wants out. I think, OK maybe I should say I hope, that this allows for an even bigger gain when they announce the first of several good news milestones that should be coming out over the next couple of months. Good luck to all longs.
  • IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017


    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
  • Chart update: Now that we have clearly broken the $7 mark (which was pretty strong resistance) it should now become support. There are some additional resistance levels above $7 but with less shares traded at these levels they should be easier to break through. Don't know exactly where PETX will go from here but onward and upward looks to be the case. JMHO
  • Chart wise if we break $7 and can hold it then upward momentum should follow... Interesting times w/chart and timing of upcoming events. Holding, like some of you have mentioned $10 by year end may come sooner than later, JMHO.
  • Also, just noticed on Yahoo stats for PETX that over 15% of shares are short, if that is true, could be good candidate for short squeeze since insiders own over the half the shares.
  • Happy to see that the future potential for this company and their field of expertise could be long term winner and finally getting some good upward movement in price per share. Go Long Aratana!
  • PETX is also benefitting from a market sector swing. Biotechs have not been on the favorites list and many are beaten down. With the economy looking like we won't have great growth, this sector is a better place to be. Also, the market has figured out that we won't have any crazy cuts to drug prices as Trumpcare is in limbo. Also, we should be seeing more M&A activity, and it will be a reminder that PETX is a great M&A target. I really think we are going to see higher and higher 12 month targets from analysts. It has taken a long time, but this is definitely starting to turn the corner.
  • Up $.35 on over 400 thousand shares on a no news day. The high volume of shares makes it more real. No reason why this stock shouldn't keep going. The executive has gotten the word out that the future is bright! Plenty of upcoming milestones to keep this moving in the right direction.
  • Positive column in Seeking Alpha published last night. Title is "Aratana: Why You Might Want To Grab A Few Shares In This Rapidly Expanding Companion Animal Market". No great new insight, just the story we all know packaged up. Hopefully it will alert the unwashed masses to PETX!
  • Last stop: William Blair 2017 Growth Stock Conference in Chicago
    Wednesday, June 14, 2017 at 9:40 a.m. ET

    It would be nice if they had something else new to talk about. Entyce status update? Nocita for cats approval? Too early for other anouncements.
  • 2017 Stifel Dental and Veterinary Conference in New York City Wednesday, May 31 at 3:35 p.m. ET

    It will be webcast live. The execs were very upbeat during the quarterly review and I expect the same here. Analysts have been raising financial expectations. It is really sad to see this stock down at this price, Maybe this will be a catalyst for the stock price.
  • Next up!
    Jefferies 2017 Global Healthcare Conference in New York City
    Wednesday, June 7, 2017 at 3:00 p.m. ET
  • I started my 10 year old Doberman (122 lbs) on 100mg of galliprant this past Thursday. Vet said he could add another 20mg if needed. After 2nd day I saw a noticble difference. He is more playful and jumped up on our bed last night, which he hadn't done for sometime. He had surgeries on both hind ACL when he was around two and has always been reluctant to let us massage towards the rear. He didn't seem to have a problem with this last night and this morning, although we were still gentle but he didn't growl like before. The down side is that it cost us $30 for 7 tablets, so that might be out of many peoples price range since NSAID's are less expensive. but I think we will stick with it. I asked the vet about response from other pet owners and he said he only has a few on it and it was too early to tell. He has been selling it since April
  • News events schedule - 3 conference presentation May 31st.- June 7th, June 14th. AT-003 approval (Nocita for cats) June - August timeframe. Q2 financial results 1st week of August. Nocita manufacturing approval Aug - Sep. Nocita launch - Sept - October. Q.3 results, 1st week in November. AT-014 Dogs conditional licensure August - November. Completion of Pivotal studies for AT-016 (Osteoarthritis pain - dogs). Oct - Dec. and AT-002 pivotal trial results for Cats, sometime in 2017 - no timeframe given.
  • Is PETX overvalued at current levels? Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awesomeSTO-CKS.
  • Either no one believes in this company, or big money people are pushing the price down to accumulate....volume is low, so I don't buy the accumulation theory...did we all over evaluate this company's prospects???
    I do not get the price in the 5.80's....
  • Took my dog to our vet yesterday and asked what he knew about Aratana. He was not familiar with company name but very familiar with Galliprant and very pleased with it. He is still familiarizing himself with it, including whether and how it can be used in dogs with compromised renal function, but he is happy to have it as a prescribing option. Sounds like he is prescribing it for more than just OA indications. He is part of a 3 vet practice. I was happy to hear that Elanco had gotten Galliprant to him.
  • Just looked at the SEC Form 4 filed on 5/19/2017 by Broadfin Capital. It shows the fund acquired 729,500 shares of Aratana at $7.50/share. What's going on here?
  • Anyone else concerned about conflicting statements from VETS as to efficacy of G?

    Don't know if the posts are serious or not, but they seem to be...would like to hear from VETS who have prescribed G....serious comments only.
  • That $6.50 area is proving to be some tough resistance!